검색
Leap Therapeutics Inc
LPTX관심 목록에 추가
2.050USD
0.0000.00%
시장 운영 시간 （ET）시세는 15분 지연됩니다
68.57M시가총액
손실P/E TTM
자세한 내용은 Leap Therapeutics Inc 회사
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc 정보
종목 코드 LPTX
회사 이름Cypherpunk Technologies Inc
상장일Jan 24, 2017
CEOOnsi (Douglas E)
직원 수52
유형Ordinary Share
회계 연도 종료Jan 24
주소47 Thorndike Street
도시CAMBRIDGE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호02142
전화16172524343
웹사이트https://www.leaptx.com/
종목 코드 LPTX
상장일Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
자주 묻는 질문
Leap Therapeutics Inc의 상위 5대 주주는 누구인가요?
Leap Therapeutics Inc의 상위 5대 주주는 다음과 같습니다: Dr. James H. Cavanaugh, Ph.D.
Leap Therapeutics Inc(LPTX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Leap Therapeutics Inc의 주식을 보유한 기관은 총 114곳이며, 이들이 보유한 주식의 총 가치는 약 11.73M로 전체 발행 주식의 12.01%를 차지합니다. 이는 2025Q4 대비 -9047212.00 증가한 수치입니다.